Risk Factors Update Summary
- The company completed enrollment in Phase 3 INFRONT-3 and Phase 2 INVOKE-2 trials in the second half of 2023.
- Potential termination clauses added for GSK, AbbVie, and Adimab agreements, impacting collaboration continuity.
- The net proceeds from the underwritten public offering were approximately $71.1 million in January 2024.
- AbbVie may opt out of developing TREM2 program, leading to loss of $250 million milestone payment.
- The FDA granted Breakthrough Therapy Designation to latozinemab for the treatment of FTD-GRN in February 2024.
- Cybersecurity risks highlighted, emphasizing potential data breaches and interruptions in operations.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1653087&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.